Alkermes Plc at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : Great. Thanks for the presentation. I guess I want to start on the on the bottom of this slide where you mentioned the plan for significant cash generation and an increased focus on capital allocation. I think you talked about expanding Alkermes capabilities, but also for potentially returning cash to shareholders. What form could that take and I guess over what time horizon are we contemplating here?

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : Great. And then expanding the pipeline in a measured way. What's the kind of I know there's an ideal mix between kind of internal and external expansion. And if we think about business development, maybe you can just touch on what Alkermes is interested in from a business standpoint?

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : Got it. When you talk about interrogating this sleep/wake cycle and yielding additional candidates. Is that additional orexin or is that sort of outside of orexin? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 10, 2024 / 7:15PM, ALKS.OQ - Alkermes Plc at JPMorgan Healthcare Conference

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : Got it. The updated narcolepsy Type 1 data you just provided, when should we expect to see kind of a more detailed either a kind of conference presentation or publication or we could see more efficacy details?

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : Got it. And then maybe switching to NT2 and IH. I think you talked about potentially a similar and next step trial design for NT2, as you're looking at NT1 and I thought you said something about enrolling more IH patients for safety, is that in the same study is a separate study?

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : So in an ideal scenario, you're starting Phase 2 in NT1 this year. When should we think about seeing the results of that trial? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 10, 2024 / 7:15PM, ALKS.OQ - Alkermes Plc at JPMorgan Healthcare Conference

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : If we fast forward, I think kind of commercially, can you just talk a little bit about where you see orexin fitting into the treatment paradigm in narcolepsy?

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : Let me come -- coming back to and from the 2024 financial projections you put out there, including the 30% EBITDA margin. Should we think of that as a sustainable margin? Is it possible to kind of expand from there to think about the balance between like kind of continued top line growth, but maybe also more R&D investment and orexin and pipeline comes forward?

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : So maybe kind of coming back around to on one of those growth drivers of all the. And so we spend a little time and your strategy to kind of continue driving the breadth and depth of prescribing, whether it;s kind of number of prescribers who have written the product who want to see writing it and kind of where that can go?

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : So is the growth we've seen so far and benefiting from the DTC campaign that started last year, you talked about kind of taking time to kick in. So is there still more to more to come?

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : And what do you estimate the mix is between Schizophrenia and Bipolar?

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : Does that change the dynamic or?

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : And maybe on the reimbursement side, where are you or what's the current formulary positioning? And are you in talks to improve that positioning

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : I think we're about out of time, so we'll stop there. Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 10, 2024 / 7:15PM, ALKS.OQ - Alkermes Plc at JPMorgan Healthcare Conference